Maravai LifeSciences Holdings Inc - Ordinary Shares - Class A
MRVI
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
57.3% downsideOvervalued by 57.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.33 Billion |
|---|---|
| Enterprise Value | $1.20 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.91 |
| Beta | 0.62 |
| Outstanding Shares | 146,426,000 |
Return
| Return on Equity | -49.42% |
|---|---|
| Return on Assets | -14.66% |
| Return on Invested Capital | -24.21% |
Valuation & Multiples
| P/E Ratio | -6.72 |
|---|---|
| PEG | 7.68 |
| Price to Sales | 4.99 |
| Price to Book Ratio | 2.5 |
| Enterprise Value to Revenue | 5.84 |
| Enterprise Value to EBIT | -7.36 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9371▲ 90.29% |
|---|---|
| Total Calls | 370,200▼ 45.99% |
| Total Puts | 346,900▲ 1382.48% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 83.70%▼ 5.74% |
|---|---|
| Total Invested | $343.73M▼ 18.44% |
| Investors Holding | 165▼ 2.00% |
ESG Score
No data
About Maravai LifeSciences Holdings Inc
3 employeesMaravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Maravai companies are ...
Relevant Senate Committees
Although advisory, this committee provides the essential 'revenue estimates' and technical expertise that shape all tax legislation. Information regarding potential changes to corporate tax structures or R&D capital investment credits would be highly material for Maravai and its customers, providing direct insight into critical fiscal policy impacts.
This committee controls taxation and trade policy, which directly impacts corporate profitability, R&D investments, and global supply chains for Maravai. It also influences the healthcare sector through Medicare pricing, affecting Maravai's customers and thus indirectly Maravai itself.
This committee directly allocates discretionary federal spending. Its subcommittees determine funding for scientific research (e.g., NIH, CDC), which is a major driver of demand for Maravai's products. Members would possess non-public material information about specific funding decisions affecting MRVI's ecosystem.
This committee directly regulates the FDA and NIH, which are critical to Maravai's industry. FDA approval processes, NIH research funding, and broader health policies directly impact Maravai's customers (biopharma, vaccine, diagnostics, cell and gene therapy companies) and the market for its products.
This committee's oversight of antitrust laws and intellectual property (IP) is highly relevant. IP protection is crucial for biotech and pharmaceutical companies like Maravai and its customers, and antitrust enforcement can impact M&A activity in the life sciences sector.
Members receive classified briefings on global threats, which explicitly includes risks related to 'biotech stocks'. Information on bio-threats, pandemics, or state-sponsored biological research could directly impact demand for Maravai's diagnostics, vaccine components, or biologics safety products.